Despite the advances in harnessing the oncogenic properties of thyroid cancer via dual administration of PI3K/Akt pathway inhibitors—palbociclib and omipalisib [92]—it is not known how dysregulated miRNAs in this context could determine the drug response. The gene discussed is AKT1; the disease is thyroid gland carcinoma.